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Observing an autistic child endlessly biting his/her own hand, banging 
their head against a wall, compulsively spinning an object, or staring 
for hours at a piece of dust is terrifying because it is impossible to 
understand how his/her mind functions. He/she seems an alien in our 
everyday world. These past few years I embarked into the world of an 
autistic child reluctantly and fearfully. As I learned about their world 
I could look at these children through new eyes and told my friends 
and family what I observed. I have tried my best to make this thesis 
as informative as I could, including aspects surrounding the 
background and known causes of this disorder. From my own 
observation and research, it seems evident that autism is not a 
psychological malfunction but rather a neurological one. However, an 
enormous amount of research still needs to be undertaken in order to 
help autistic children and to understand their bewildering and often 
self-destructive behaviour. 
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ABSTRACT 
 
Autism is a pervasive developmental disorder (PDD) that’s incidence is approximately 1 in 
158. It is four times more prevalent in males than females and is believed to be caused by 
both genetic and environmental factors. Research indicates that several genes are involved in 
autism and it is believed that these genes act together to produce autism. Many genes 
implicated in this disorder are involved with brain structure formation and brain functioning. 
Studies have identified the reelin (RELN) gene as necessary for proper formation of brain, 
which indicates that RELN abnormalities could contribute to the aetiology of several 
neurogenetic diseases such as schizophrenia, bipolar and autism. The aims of the study were 
(i) to genotype two SNPs (exonic rs3622691 and intronic rs736707) in the RELN gene using 
Taqman® SNP Genotyping assays to detect association with autism in three distinct South 
African (SA) ethnic groups (Black, Caucasian and Mixed), and (ii) to detect candidate genes 
that are over and under-expressed in the samples taken from a SA Caucasian autistic group 
and compare those with samples taken from a healthy Caucasian group using cDNA 
microarray. The Taqman® study indicated significant association for the intronic SNP, 
rs736707, with a p-value of 0.0009 in the total SA group. More so, the Mixed group 
displayed the highest significance amongst the ethnic groups, with a p-value of 0.00014. The 
microarray study yielded 21 genes with 95% significance in the Caucasian sample group. 
Most genes were hypothetical proteins and formed part of the FAM90A family. The 
LOC83459 showed the highest level of expression in the autistic samples, while the BTNL8 
gene was shown to be highly suppressed in the control samples. 
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1.1 BACKGROUND 
In 1911 Eugen Bleuler, a Swiss psychiatrist, was the first person to use the term Autism 
(Ozand et al. 2003). However, the term he used applied to adult schizophrenia. Due to this, in 
the 1940's the medical community felt that children who had autism where schizophrenic. 
Autism was eventually discovered by psychologist Leo Kanner in 1943 (Wing 1993). Before 
Leo Kanner’s classification, autistic children were classified as emotionally disturbed or 
mentally retarded. The common features amongst his patients included a profound lack of 
emotional contact with others, an intense wish for sameness in routines, muteness or 
abnormality of speech, fascination with manipulating objects and high levels of visio-spatial 
skills. In addition, he also noted that these children often did not demonstrate capabilities that 
showed that they were slow learners nor did they fit the patterns of emotionally disturbed 
children. Kanner’s observations became the criteria for early studies of the prevalence of 
autism. Individuals with these features have the full triad of impairments and represent the 
most severely disabled end of the autism spectrum of disorders (ASD) known as Classic 
Autism. During the 1960's researchers had a better understanding of autism and identified 
autistic symptoms and treatment with more precision. Kanner’s findings led to the formation 
of autism organizations in the 1960’s and 1970’s by the parents of children with autism 
(Wing 1993; Bailey et al. 1995). 
1.1.1 What is autism? 
Autism is a pervasive developmental disorder (PDD) and can also be termed as ‘Classic 
Autism’ (Bailey et al. 2005). This disorder affects some children from birth or infancy and 
leaves them unable to form normal social relationships or to develop normal communication 
skills (Rutter 2005). Its incidence is approximately 1 in 158 in the United States of America 
(Autism South Africa 2008). The statistics for South Africa are not yet known. Autistic males 
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outnumber females by 4 to 1 (Wing 1993) and there is no explanation as to why the 4:1 ratio 
exists. However, some scientists seem to think that autism could be X-linked. Therefore, 
since the female has XX chromosomes and the male XY chromosomes, the reason for this 
phenomena could be due to the protective X allele of the female; i.e. if autism is indeed X-
linked and the X allele of the male is affected, then he would not have another X allele to act 
as a protective allele (Skuse 2000). The autistic child is unable to use language meaningfully 
or to process information from the environment. About half of all autistic children are mute, 
and those who do speak often only repeat mechanically what they have heard (Santangelo 
and Tsatsanis 2005). Other characteristics of autism include an uneven pattern of 
development, a fascination with mechanical objects, a ritualistic response to environmental 
stimuli, and a resistance to any change in the environment. Some autistic children have 
precocious ability, such as mathematical skill. At present, early diagnosis of autism is still 
rare, but scientists are currently working towards improving the diagnostic tools to achieve 
this goal (Fombonne 2003). The diagnosis of autism is only made if three types of behaviour 
are present. These behavioural types include; whether the child’s social relationships and 
social development are abnormal, whether the child is failing to develop normal 
communication, and whether the child’s interests and activities are restricted and repetitive 
rather than flexible and imaginative (LeCouteur et al. 1989)  
Several studies have revealed abnormalities in different regions of the brain of an autistic 
individual. At present, various techniques are used to obtain these regions of the brain 
including Computer Axial Tomography (CAT) scans and Magnetic Resonance Imaging 
(MRI) scans (fig. 1.1). The areas of abnormality noted include; abnormalities in the frontal 
lobes, which are the areas in the brain responsible for planning and control; abnormalities in 
the limbic system, which are the part of the brain responsible for emotional regulation; and 
 
 
 
 
8 
 
abnormalities in the brain stem and cerebellum, which governs motor coordination 
(Courchesne et al. 2001).   
 
Fig. 1.1: In this MRI image, the person with autism (left) has a smaller cerebellum than the normal                                  
               brain (right) [Pfizer 2001]   
 
*Cerebellum region circled and indicated in blue 
 
1.2 WHAT CAUSES AUTISM? 
It seems likely, given the research so far, that several factors combine to cause autism. 
However, no one really knows for sure what causes autism. Modern medical evidence 
suggests clear biological causes for autism such as genetic factors, viral infections, and 
birth or pregnancy complications; any of which may cause the subtle brain damage 
assumed to produce autism. Mothers of autistic children often report difficulties in 
pregnancy and labour. Other conditions such as viral infections, metabolic conditions and 
genetic abnormality are also closely related to autism. It is therefore believed that the 
causative agents of autism can be noted as either environmental or genetic, or consequently, 
a combination of both these factors (Santangelo and Tsatsanis 2005). 
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1.2.1 Environmental effects on autism 
 
Exposure to a broad array of external factors and measurements of important physiologic 
factors are believed to be a causative part in autism. These factors include environmental 
exposures from chemicals used in industrial processes, consumer products, illnesses of the 
mother during pregnancy and of the child after birth, medications and vaccinations, as well 
as diet (Lawler et al. 2004). Clinicians and psychologists believe that by looking at 
children’s medical history, environmental exposure to toxins, and many other aspects of 
their lives, both before and after birth, possible causes and contributing factors to autism 
may be evaluated. No clear picture has emerged from research into environmental 
contributors to autism, however, clues are available to support this theory (Santangelo and 
Tsatsanis 2005). 
 
1.2.1.1 Pre and post-natal exposure 
In utero, exposure to the rubella virus (the cause of German measles) can impair brain 
development of the fetus thus leading to varying degrees and combinations of blindness, 
deafness, birth defects, mental retardation as well as autism. Children with autism resulting 
from exposure to rubella virus may improve, worsen, or remain the same. Post-natal herpes 
simplex virus brain infections (encephalitis) may also result in an autism-like syndrome. 
Also, the morning-sickness drug, thalidomide, is best known for the tragic and severe limb 
defects that it caused in the offspring of some women who take it while pregnant (Desmond 
et al. 1967). 
 
A 1994 Swedish study done by Stromland et al. reported that five out of a group of 100 
children who had been exposed to the morning-sickness drug thalidomide in utero had 
developed autism. The risk was particularly increased when the exposure to the drug 
occurred early in pregnancy, that is, 20-24 days after conception. Subsequently, in an 
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autopsy examination of a person with autism, abnormalities in the brain stem and cranial 
nerves were detected. This kind of abnormality is best explained by altered brain 
development during early gestation, similar to the time of increased risk in people exposed 
to thalidomide (Aronson et al. 1997). 
 
1.2.1.2 Chemical exposure 
 
It was found that there were reports of chemical exposures that are potentially related to 
autism. Preconception parental occupational exposure to chemicals and maternal abuse of 
drugs have been linked to autism in offspring (Grandjean and Landrigan 2006). Maternal 
use of alcohol during pregnancy can result in fetal alcohol syndrome as well as intellectual 
and behavioral problems. Asperger syndrome and autism can coexist with other 
manifestations of fetal alcohol syndrome, suggesting that alcohol may be responsible for 
autism as a result of early gestational exposures (Harris et al. 1995). 
 
1.2.1.3 Mercury and vaccine exposure 
Vaccine-related concern stems from the use of thimerosal as a preservative in vaccine 
preparations. Thimerosal is an organic mercury compound, which metabolises to 
ethylmercury and thiosalicylate (Hessel 2003). It has been used in vaccines since the 1930s 
until it began to be phased out in the late 1990s. Concerns centered on the observation that 
organic mercury is a potent toxic agent in the developing brain and that children receiving a 
full set of recommended vaccinations were often exposed to mercury at levels that exceed a 
“safe” reference dose (Halsey and Goldman 2003). 
 
 However, thimerosal is not the largest source of mercury exposures in people, despite 
concerns on the administration of mercury-containing vaccines to pregnant women, infants, 
and children. Mercurials may be found in drugs for the eye, nose, ear, skin, and throat, 
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tooth pastes, antiseptics, disinfectants, contraceptives, in dental fillings and thermometers, 
and many other products. Recent studies have indicated that molecular mercury exposure 
can induce death, disorganization and/or damage to selected neurons in the brain similar to 
that seen in recent ASD brain pathology studies, and this alteration may likely produce the 
symptoms by which ASDs are diagnosed (Blaxil et al. 2003). Methyl mercury easily 
crosses the placenta and can thus impact normal fetal brain development. Therefore, 
mercury exposures from various sources must be considered when assessing a link between 
autism and mercury. Fortunately for the US and European countries, thimerosal-free 
vaccines are now available so parents are not faced with questioning the safety of vaccines 
for this reason (Geier et al. 2008). 
 
1.2.2 Genetics as a cause of autism 
 
Genes account for traits of growth, development, and physical characteristics. At conception 
a baby receives genes from both parents. There are about 100 000 genes in the body, each 
instructing cells how to grow and survive. Genes are made up of DNA and when an error 
occurs in any of these genes, a genetic disorder may result. Since genetic makeup also 
regulates brain development, several researchers have explored heredity as a cause of autism. 
Recent studies have pinpointed certain forms of genetic disorders that lead to symptoms of 
autism (Sykes and Lamb 2007). 
 
 
1.2.2.1 Twin studies 
Identical twins (known as monozygotic twins - MZ) come from the same fertilized egg and 
are therefore genetically identical. In contrast, non-identical (or dizygotic - DZ) twins 
develop from two separately fertilized eggs and are therefore not genetically identical. Twin 
studies are a design in behavior genetics that aid the study of individual differences by 
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highlighting the role of genetic causes on behaviour. Twins are invaluable for studying 
important questions because they disentangle the sharing of genes and environments. If we 
observe that children in a family are more similar than might be expected by chance, this may 
reflect shared genes inherited from parents. Twin studies compare the similarity of MZ twins 
who share 100% of their genes, to that of DZ twins, who share only 50% of their genes 
(Muhle et al. 2004). These studies have been performed for autism and indicated that if one 
MZ twin has autism then there’s a 60% chance that the other will also be affected as 
compared to 0% in the case of DZ twins (fig 1.2). When broader autism phenotypes are 
included, for example communication skills and social disorder, the concordance rises to 60-
92% in MZ twins and 0-10% in DZ twins. Thus, this evidence suggests that a genetic cause 
does exist for autism (Bailey et al. 1995). 
 
 
Fig. 1.2: Estimated heritability between MZ and DZ twins (Rosenberg et al. 2009) 
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1.2.2.2 Genetically inherited disorders 
Several inherited disorders are associated with autistic-like behavior. Some of these 
disorders include Fragile X Syndrome, Tuberous Sclerosis Complex (TSC) as well as 
Phenylketonuria (PKU) [Muhle et al. 2004]. Fragile X only occurs in a small proportion of 
children with autism (under 10%); but this percentage nevertheless makes it the most 
common cause of autism yet identified. A child with Fragile X Syndrome is usually 
mentally handicapped and often has an unusual facial appearance (Zafeiriou et al. 2007).  
 
Studies have also indicated that autism is quite common in children with TSC (Gutierrez et 
al. 1998). However, this condition is itself very rare and is an uncommon cause of autism. 
The features of TSC may include unusual skin pigmentation, a particular facial rash, and 
most tragically, the growth of tumours in the brain. Tuberous sclerosis may also give rise to 
a special form of epilepsy known as infantile spasms. This epilepsy has also been proposed 
as a cause of autism, so it is possible that the link between autism and TSC merely reflects 
the common association with infantile spasms (Deonna and Roulet 2006).  
 
Another genetic condition which may lead to autism includes PKU, which is also an 
inherited condition involving an inability of the body to break down the naturally occurring 
chemical phenylalanine (Baieli et al. 2003). As a consequence there is a build-up of related 
toxins in the body, and these in turn may damage the brain (Waisbren et al. 2007). 
However, in many countries, newborn children are tested in the first week of life to identify 
PKU using a ‘heel prick’ blood test. Treatment starts immediately if PKU is identified in 
the newborn child. Therefore, autism due to PKU has become very rare (Therrell and 
Adams 2007). 
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1.2.2.3 Susceptibility genes 
In spite of vigorous genetic studies, no single causative or susceptibility gene common in 
autism has been identified. Thus, multiple susceptibility genes in interaction are considered 
to account for the disorder. Since the identity and number of genes involved remain 
unknown, the wide phenotypic variability of autism likely reflects the interaction of 
multiple genes within an individual's genome and the existence of distinct genes and gene 
combinations among those affected (Folstein and Rosen-Sheidley 2001).  
 
There are three main approaches to identifying chromosomal regions likely to contain 
relevant genes. These include: Whole genome screens that search for linkage of autism to 
shared genetic markers in populations of multiplex families (families with >1 affected 
family member), cytogenetic studies that may guide molecular studies by pointing to 
relevant inherited chromosomal abnormalities in affected individuals and their families, as 
well as evaluation of candidate genes known to affect brain development in these 
significantly linked regions (Bartlett et al. 2005).  
 
Data from whole-genome screens in multiplex families suggest interactions of at least 10 
genes in the causation of autism. Scientists have also discovered that a putative speech and 
language region at 7q31-q33 seems most strongly linked to autism, with linkages to 
multiple other loci under investigation. Cytogenetic abnormalities at the 15q11-q13 locus 
are fairly frequent in people with autism, and a chromosome 15 phenotype was described in 
individuals with chromosome 15 duplications (Ashley-Koch et al. 2006). Among other 
candidate genes known to be involved in autism are the neuroligin 3 (NLGN3), Forkhead 
box protein P2 (FOXP2) and the reelin (RELN) gene at 7q22 (table 1.1) [Bartlett et al. 
2005].  
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Table 1.1: Candidate susceptibility genes in autism (www.genetests.org) 
 
Gene Symbol Chromosome Locus Gene/Protein Function
References Test 
Availability Pro 1  Con 2  
SLC25A12  2q24 
Mitochondrial 
aspartate/glutamate 
carrier 
Ramoz et al 2004    
C4B  6p21  Complement component Odell et al 2005    
GLO1  6p21 Zinc metalloenzyme scavenges oxoaldehydes Junaid et al 2004   
Research 
only 
GRIK2  6q21 
Glutamate receptor 6 
involved in neural 
development 
Jamain et al 2002 , 
Shuang et al 2004   
HOXA1  7p15-p14.2 
Homeobox gene 
involved in hindbrain 
development 
Ingram et al 2000 , 
Conciatori et al 2004 
Devlin et al 2002 , 
Li et al 2002 , 
Talebizadeh et al 
2002 , Collins et al 
2003 , Romano et 
al 2003 , 
Gallagher et al 
2004  
RELN  7q22.1 
Signaling protein 
involved in neuron 
migration 
Persico et al 2001 , 
McCoy et al 2001, 
Zhang et al 2002  
Krebs et al 2002 , 
Devlin et al 2004 , 
Li et al 2004  
WNT2  7q31 
Signaling proteins 
involved in embryonic 
patterning, cell 
proliferation and cell 
determination 
Wassink et al 2001 , 
Hutcheson et al 2004 
McCoy et al 2002 
, Li et al 2004  
FOXP2  7q31 
Transcription factor 
involved in 
embryogenesis and 
neural functioning 
Gong et al 2004 , Li 
et al 2005  
Gauthier et al 
2003 , Wassink, 
Piven et al 2002  
UBE2H  7q32 
Ubiquitin-dependent 
proteolytic system 
enzyme 
Vourc'h et al 2003   
EN2  7q36.2 
Homeobox gene 
involved in midbrain 
and cerebellum 
development 
Petit et al 1995 , 
Gharani et al 2004  Zhong et al 2003  
PTEN  10q23.31 Tumor suppressor  Butler et al 2005   
HRAS  11p15.5 
Oncogene GTPase 
involved in cell 
division, differentiation 
and apoptosis 
Herault et al 1995 , 
Comings et al 1996   
AVPR1A  12q14-q15 
Arginine vasopressin 
receptor involved in 
social behavior 
Kim, Young et al 
2002 , Wassink et al 
2004  
 
UBE3A  15q11-q13 
Angelman syndrome 
causative gene encodes 
ubiquitin protein ligase 
Nurmi et al 2001 , 
Jiang et al 2004  
Nurmi, Dowd et al 
2003  
ATP10C  15q11.2-q12 
Phospholipid transporter 
involved in CNS 
signaling  
Nurmi, Amin et al 
2003  
Kim, Herzing et al 
2002  
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GABRB3, 
GABRA5, 
GABRG3  
15q11.2-q12 GABA receptor subunits 
Cook et al 1998 ; 
Martin et al 2000 ; 
Nurmi et al 2001 ; 
Buxbaum et al 2002 ; 
Nurmi, Dowd et al 
2003 ; Menold et al 
2001 ; Shao et al 
2003 ; McCauley et 
al 2004  
Nurmi et al 2001 , 
Maestrini et al 
1999 , Salmon et 
al 1999  
SLC6A4  17q11.1-q12 Serotonin transporter  
Cook et al 1997 , 
Klauck et al 1997 , 
Yirmiya et al 2001 , 
Tordjman et al 2001 , 
Kim, Cox et al 2002 , 
Conroy et al 2004 , 
Mulder et al 2005  
Persico et al 2000 , 
Persico et al 2002 , 
McCauley et al 
2004  
NF1  17q11.2 Ras protein regulation Mbarek et al 1999 , Marui et al 2004  Plank et al 2001  
HOXB1  17q21-q22 
Homeobox gene 
involved in hindbrain 
development 
Ingram et al 2000  
Li et al 2002 , 
Romano et al 2003 
, Gallagher et al 
2004  
APOE2  19q13.2 
Lipoprotein receptor 
involved in neuronal 
migration and lipid 
transport 
Persico et al 2004   
ADA  20q13.12 Purine metabolism and immune response 
Young et al 1999 , 
Kim, Young et al 
2002  
 
NLGN3  Xq28 ?13 Neural synapse formation Jamain et al 2003   
Clinical  
 
NLGN4X  Xp22.33 Neural synapse formation 
Jamain et al 2003 , 
Laumonnier et al 
2004  
Talebizadeh et al 
2004 , Gauthier et 
al 2005 , Vincent 
et al 2004  
ARX  Xp22.13 Homeobox gene Stromme et al 2002 , Turner et al 2002   
Research 
only 
 
* List of gene names are in glossary section 
Based on a variety of analysis types including linkage, association, allele sharing, transmission 
disequilibrium, subset analysis using SNPs, coding polymorphisms, and specific mutations 
1. Pro = study supporting candidate gene assignment 
2. Con = study not supporting candidate gene assignment 
 
 
1.3 SINGLE NUCLEOTIDE POLYMORPHISMS (SNPs) 
SNP’s common variations that occur at a frequency in every 300 nucleotides, which means 
there are roughly 10 million SNPs in the human genome. These variations can be used to 
track inheritance in families. Each SNP represents a difference in a nucleotide. For example, a 
SNP may replace the nucleotide cytosine (C) with the nucleotide thymine (T) in a certain 
stretch of DNA. SNPs occur normally throughout a person’s DNA. Most commonly, these 
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variations are found in the DNA between genes. They can act as biological markers, helping 
scientists locate genes that are associated with various diseases. When SNPs occur within a 
gene or in a regulatory region near a gene, they may play a more direct role in disease by 
affecting the gene’s function (Aritoshi et al. 2004). 
 
Most SNPs have no effect on health or development. However, some of these genetic 
differences have proven to be very important in the study of human health. Researchers have 
found SNPs that may help predict an individual’s response to certain drugs, susceptibility to 
environmental factors such as toxins, and risk of developing particular diseases. SNPs can 
also be used to track the inheritance of disease genes within families. Future studies will work 
to identify SNPs associated with complex diseases such as heart disease, diabetes, and cancer
(Shen et al. 2009). 
 
Several types of genetics variations occur in humans; namely:  insertions and deletions of 
repetitive DNA (e.g. Fragile X Syndrome, Huntington's Disease), smaller duplications and 
deletions of genes (e.g. lactase) and point mutations that result in single base pair 
substitutions or deletions (e.g. Sickle Cell Anaemia) [fig. 1.3]. Each of these types of variation 
requires different diagnostic tests. The earliest, common SNP diagnostics were Restriction 
Fragment Length Polymorphisms (RFLP) tests and Polymerase Chain Reaction (PCR). Since 
SNP’s have become more understood, the methods for detecting them have been rapidly 
modified and improved (Fors et al. 2000). One such advanced method for SNP detection is 
known as Taqman® SNP Genotyping Assay (Morita et al. 2006) 
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Fig. 1.3: Different forms of genetic variations (SNPS) 
(http://urgi.versailles.inra.fr/projects/GnpSNP/general_documentation.php) 
 
1.3.1 SNPs associated with Autism 
Turunen et al. 2008 reported that two SNPs (rs2056202 and rs2292813) within the 
Mitochondrial Aspartate/Glutamate Carrier SLC25A12 were shown to be strongly associated 
with autism. Family-based association analysis was performed in two samples with different 
phenotypic characteristics. The samples included 97 Finnish families with autism and 29 
extended families with Asperger syndrome (AS). They detected an association at rs2292813 
(FBAT, P=0.0018) in the autism samples but no association was found in the AS samples.  
 
Another study done by Rehstrom et al. (2008) showed a significant linkage peak identified at 
3q25-27 where a genome-wide linkage screen for ASD in Finnish families was performed. 
Eleven positional and functionally relevant candidate genes at 3q25-27 were tested for 
association with autistic disorder. Genotypes of 125 SNPs were determined in 97 families 
where at least one individual was affected with autism. The most significant association was 
observed using two non-synonymous SNPs in HTR3C; namely: rs6766410 and rs6807362. 
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Sequencing revealed no other variants in the coding region or splice sites of HTR3C. They 
proposed that HTR3C represents a novel candidate locus for ASDs and should be tested in 
other populations. 
 
Vernes et al. 2008 hypothesized that neural pathways downstream of FOXP2 gene influences 
more common phenotypes, such as specific language impairment. They tested for associations 
between SNPs in this gene and language deficits in a well-characterized set of 184 families 
affected with specific language impairment evident in autistic individuals. They found that 
FOXP2 down-regulates the CNTNAP2 gene, which is expressed in the developing human 
cortex. On analyzing CNTNAP2 polymorphisms in children with typical specific language 
impairment, they detected significant associations with nonsense-word repetition, a heritable 
behavioural marker of this disorder at rs17236239. This region coincides with one associated 
with language delays in children with autism. They concluded that the FOXP2-CNTNAP2
pathway provides a mechanistic link between distinct syndromes, such as autism, which 
involves disrupted language. 
 
 
1.4 THE REELIN (RELN) GENE 
The RELN gene consists of 65 exons spanning approximately 450 kb and is mapped at 
chromosome 7q22 (fig. 1.4). It is found in the spinal cord, brain, blood and other body organs 
and tissues. Reelin plays a pivotal role in the development of the cerebral cortex, cerebellum, 
hippocampus and several brainstem nuclei (Persico et al. 2001). One of the most distinct 
effects of the RELN deletion is abnormal formation of the cerebral cortex in reeler mice. 
Studies have identified RELN as necessary for proper formation of brain. This indicates that 
RELN abnormalities could contribute to the aetiology for several neurogenetic diseases. 
RELN protein levels are significantly reduced in multiple brain areas of patients with 
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schizophrenia and bipolar disorder. This suggests that persisting low RELN levels in the 
developed brain increases vulnerability to schizophrenia, thus inducing damage (Kim and 
Webster 2009). Similar abnormalities have been seen for RELN levels in autistic individuals.
Blood levels of unprocessed reelin are significantly reduced in autistic twins, their fathers, 
their mothers, and their phenotypically normal siblings versus controls (Fatemi et al. 2002) 
 
Serajee et al. 2006 reported that two SNPs in intron 59 (rs736707) and exon 22 (rs362691), 
located on the RELN gene, has shown significant association in individuals with autism. 
Their study was based on sample analysis of Caucasian individuals ascertained through the 
Autism Genetics Resource Exchange (AGRE). They suggested a role for RELN as a 
candidate gene in the aetiology of autism. My study was based on these two SNP’s in order 
to detect whether they have a significant association in the South African autistic 
population.  
 
 
 
Fig. 1.4: RELN gene located on chromosome 7q22 (www.genecards.org) 
 
 
1.5 WHAT IS MICROARRAY? 
DNA microarray analysis is one of the fastest-growing technologies in the field of genetic 
research. It allows for the measurement of every gene that is present in a cell or tissue 
sample, thus indicating the biological processes occurring in a cell. By comparing gene 
expression profiles from two different cell types, one could detect what makes cells different 
from one another (Gibson 2003). Insights into disease have been one of the most beneficial 
results of microarray technology. The recognition of the reduction of gene expression during 
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a disease can point researchers in important directions. This is because genes that are lost 
during a disease are typically involved in a cellular function that directly or indirectly 
prevents the disease from occurring. Therefore, identification of these genes with a 
microarray brings about the potential for targeted therapies (Netterwald 2006).  
1.5.1 Microarray techniques  
1.5.1.1 Oligonucleotide arrays 
 
Oligonucleotide arrays use small 25 base pair gene fragmented DNA to be spotted onto an 
array. Eleven to 16 copies of the DNA are placed onto the array. These DNA fragments, 
called probes, are selected in such a way that they possess little cross-reactivity with other 
genes. Hence, non-specific hybridization will be minimized. However, some non-specific 
hybridization is bound to occur, therefore, a second probe that is identical to the first (except 
for a mismatched base at its centre) is placed next to the first. This is called the Perfect 
Match/Mismatch (PM/MM) probe strategy. The arrays are printed using a combination of 
photolithography chemistry. This technique allows the probes to generate simultaneously and 
relatively quickly (Miller and Tang 2009).  
 
Production begins with a quartz wafer. This wafer is washed with a blocking compound that 
can be removed by exposure to light. Then, a mask is used, which allows light to pass 
through areas where a specific nucleotide is needed. The quartz wafer is then washed with a 
solution of the desired nucleotide that is linked to the same blocking compound, causing the 
nucleotide to attach to the probes that were exposed to light, while the nucleotide-attached 
blocking compound ensures that all of the probes are protected again. The array is now ready 
for a new mask and the addition of a new nucleotide, a process that is repeated until all of the 
probes are complete (Primrose and Twyman 2006). 
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Fig. 1.5: Production of an Affymetrix Genechip (http://www.scq.ubc.ca/spot-your-genes-an-overview-of-
the-microarray/) 
 
Once the oligonucleotide array is constructed, it is ready for use in the laboratory. The array 
is generally used to quantify the amount of mRNA in a single sample or to compare two 
different samples hybridized to two separate arrays. Samples are prepared by extracting 
mRNA from a specific sample and turning it into back into DNA through a process that 
involves the reverse transcription of the mRNA into cDNA. This is followed by a labelling 
step during which the cDNA is then transcribed to cRNA while incorporating a label (e.g. 
biotin). Once labelled, the sample of cRNAs can be hybridized to the array and bound by the 
various oligonucleotide probes. A staining reaction is also performed in order to visualize the 
amount of hybridization (fig. 1.6) [Primrose and Twyman 2006; Leung and Cavalieri 2003]. 
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Fig. 1.6: The use of Oligonucleotide arrays. mRNA is extracted from cells and amplified through a 
process that labels the RNA for analysis. The sample is then applied to an array and any bound RNA 
stained (http://www.scq.ubc.ca/spot-your-genes-an-overview-of-the-microarray/) 
 
1.5.1.2 cDNA arrays  
 
A cDNA array uses the same principle as the oligonucleotide array. However, the probes are 
larger pieces of DNA that are complementary to the genes of interest. These are called 
cDNA. These cDNA probes needed for making the array can be generated from a 
commercially available cDNA library. Polymerase Chain Reaction (PCR) can also be used to 
amplify specific genes from genomic DNA to generate cDNA probes. Once the cDNA probes 
are prepared they can be mechanically spotted onto a glass slide. This normally occurs in 
duplicate, in order to serve as controls. An experiment using a cDNA microarray involves the 
preparation of two samples for hybridization to the array: namely; a control sample and an 
experimental sample (Leung and Cavalieri 2003). These samples are prepared the same way 
for the other array, with mRNA being extracted from cells and reverse transcribed into 
cDNA. There is, however, one exception; during reverse transcription, a fluorescent dye is 
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incorporated into the newly formed cDNA. A different dye is used to label different samples. 
For example, the control sample can be labelled with a green-fluorescing dye and the 
experimental sample labelled with a red-fluorescing dye. Since the samples are labelled with 
different colours, they can be combined and hybridized to the microarray at one time. The 
two samples will competitively bind to the probes on the array and the sample containing 
more gene expression for a particular probe will ‘win’. That is, if there is more of an mRNA 
transcript in the experimental sample than in the control sample then more red dye will bind 
to the probe on the array and the spot will fluoresce red. If there is more control transcript, the 
reverse will happen and the spot will fluoresce green. When the two samples have the same 
amount of transcript, the dyes will cancel each other out and the spot will fluoresce yellow 
(fig. 1.7) [Sharlon et al. 1996]. 
 
Fig. 1.7: An example of a cDNA Microarray experiment. RNA is extracted from two different samples 
and converted into complementary DNA (cDNA), during which the DNA is labelled with florescent 
compounds. Differences in gene expression are revealed by fluorescent patterns on the array 
(http://www.scq.ubc.ca/spot-your-genes-an-overview-of-the-microarray/) 
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Table 1.2: Oligonucleotide Array vs cDNA Array  
OLIGONUCLEOTIDE ARRAY cDNA ARRAY 
Greater hybridization specificity due to 
PM/MM probe design  
Eliminates the need for probe design 
More specific florescent detection Entire genome on the array is represented 
easily 
Useful for monitoring expression levels of a 
differentially sliced transcript 
Useful for analysis of gene expression on a 
global level 
 
1.5.2 Recent microarray studies in autism 
Marshall et al. 2008 identified structural variation (copy number variation [CNV] including 
deletion and duplication, translocation, inversion) of chromosomes in some individuals with 
autism, but the full etiologic role is unknown. They performed genome-wide assessment for 
structural abnormalities in 427 unrelated ASD cases via single-nucleotide polymorphism 
microarrays. The microarray data revealed 277 unbalanced CNVs in 44% of ASD families 
that were not present in 500 controls. 
 
Microarray analysis was also used to compare the mRNA expression profile in 
lymphoblastoid cells from males with autism due to a fragile X mutation (FMR1-FM), or a 
15q11-q13 duplication [dup(15q)], and non-autistic controls. Gene expression profiles 
distinguished autism from controls and separated individuals with autism based on their 
genetic aetiology. Sixty-eight genes were identified that were dysregulated in the autistic 
samples with FMR1-FM and dup (15q) [Nishimura et al. 2007]. 
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1.6 AIMS OF THE PROJECT 
The aims were: 
• To determine whether 2 SNPs in the RELN gene are associated with autism in a South 
African population using the Taqman® SNP Genotyping Assay.  
• To detect candidate genes that are over and under-expressed in the samples taken 
from a South African Caucasian autistic group and compare those with samples taken 
from a healthy Caucasian group using cDNA microarray (pilot study). 
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2.1 ETHICAL CLEARANCE 
Ethical clearance was obtained from the UWC ethics committee and permission to work with 
autistic individuals was obtained from the Western Cape Education department. Approval for 
blood sample collection for the microarray study was obtained from the principals of Vera 
school and Groote Schuur, Cape Town. Approval for DNA cheek cells for the Taqman® 
study was obtained from principals of various autistic and healthy schools in Cape Town, 
Gauteng and Kwazulu-Natal. Letters (Appendix I and II) and consent forms (Appendix III) 
were issued to the willing parents of the learners.  
 
2.2 SAMPLE COLLECTION 
Funding allowed for only one ethnic group to be used in this study, hence blood samples 
were collected from three high-functioning Caucasian males and three low-functioning 
Caucasian males affected with autism. Blood samples were also taken from three healthy 
Caucasian males, which were used as controls. All children were between the ages of 8 and 
12 years old. The high-functioning and low-functioning status was based on the Griffiths test, 
which helps to pinpoint areas of strength and difficulty of their developmental ability (Benatti 
et al. 1986). The blood samples were drawn by three senior sisters and stored in an EDTA 
tube (BD-Plymouth, UK) at -80oC. 
 
DNA cheek samples were collected from autistic individuals from Cape Town, Gauteng and 
Kwazulu-Natal. Control samples were collected from ordinary primary schools in Cape 
Town. Samples were collected from 171 autistic individuals, 249 normal individuals and 11 
families. Of the total of 420 samples collected 176 were Black (of African descent), 114 were 
Caucasian (white) and 128 were Coloured (of mixed ancestry). Individuals partaking in the 
study were swabbed by taking a sterile swab (Sterile Dacron Polyester Tipped Applicators, 
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South Africa) and rubbing it against the inside of their cheek for 1 minute and placing it into 
a labelled sterile 15ml grinder tube (Greiner Bio-One, Austria). This was done for both 
cheeks. 
 
2.3 RNA ISOLATION FROM BLOOD 
RNA for the microarray study was isolated using the High Pure RNA Isolation Kit (Roche, 
Switzerland). The protocol was as follows: 
 
1 ml of Red Blood Cell Lysis Buffer was added to a sterile 1.5 ml microfuge tube. Thereafter, 
500 µl of human blood sample was added to the tube and the solution was mixed by 
inversion. The microfuge tube containing the sample was then manually inverted periodically 
for 10 min. It was then centrifuged (Eppendorf Centrifuge 5415D, Germany) for 5 min at 
2500rpm. Once the red, clear supernatant was carefully removed, 1 ml of red cell lysis buffer 
was added to the white pellet and resuspended by flicking the tube. The sample was then 
centrifuged (Eppendorf Centrifuge 5415D, Germany) for 3 min at 25000rpm. The 
supernatant was once again carefully removed and the white pellet was resuspended in 200 µl 
PBS. To the tube, 500 µl lysis/binding buffer was added and the sample was vortexed for 15 
sec. The entire sample was then added to a high pure filter tube, which was then inserted into 
a collection tube. The tube assembly was then centrifuged (Eppendorf Centrifuge 5415D, 
Germany) for 15 sec at 500rpm. The filter tube was then removed from the collection tube 
and the flow through was discarded. The filter tube was once again inserted into the used 
collection tube and 90 µl of DNase incubation buffer, together with 10 µl of DNase1 mix, 
was added to the filter tube. The tube was then incubated for 15 min at room temperature.  
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Thereafter, 500 µl of Wash Buffer I was added to the filter tube and centrifuged (Eppendorf 
Centrifuge 5415D, Germany) for 15 sec at 500rpm. The flow through was then discarded and 
the filter tube was once again inserted into the used collection tube. The previous step was 
then repeated using Wash Buffer II. A further 200 µl of Wash Buffer II was added to the 
filter tube and centrifuged (Eppendorf Centrifuge 5415D, Germany) for 2 min at 13200rpm. 
The collection tube was then discarded and the filter tube was inserted into a sterile 1.5 ml 
microfuge tube. Thereafter, 50 µl of elution buffer was added to the filter tube and 
centrifuged (Eppendorf Centrifuge 5415D, Germany) for 1 min. The microfuge tube then 
contained the eluted RNA. The eluted RNA was stored at –80oC before being used for cDNA 
synthesis. 
 
2.4 DNA EXTRACTION FROM CHEEK CELLS 
DNA was extracted from the swabs using the BuccalAmpTM DNA Extraction Kit (Epicentre, 
USA). The protocol was as follows: 
 
A piece of the swab tip was cut using a sterile blade and placed into a 2 ml microfuge tube to 
which 250 µl of QuickExtract DNA extraction solution 1.0 was added. The tubes were then 
incubated at 65oC for 1 min. They were then mixed by vortexing for 15 sec. The tubes were 
then incubated at 98oC for 4 min. Thereafter they were vortexed once again for 15 sec. The 
swab tip was then removed with a sterilized tweezer and the tubes were stored at –20oC. 
 
2.5 QUANTITATION OF DNA 
The concentration of each DNA sample was determined using the NanoDrop® ND-1000 
spectrophotometer (NanoDrop Technologies, USA).  
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2.6 TAQMAN® SNP GENOTYPING ASSAY 
Genotypes were determined using the Taqman® SNP Validated Genotyping Assay (Applied 
Biosystems, USA). This is a real-time PCR method that accumulates amplified product 
during the exponential phase of the PCR cycle. Combining thermal cycling, fluorescence 
detection, and application-specific software it enables the cycle-by-cycle detection of the 
increase in the amount of nucleic acid sequences. Each SNP assay consists of two primers 
used for amplification as well as two minor groove binding (MGB) fluorescent probes used 
for allele detection. The two probes, vic and fam, detect the presence of alleles 1 and 2, 
respectively. Each probe contains a reporter dye at the 5’ end and a quencher at the 3’ end. 
When vic or fam probes fluoresce, this indicates homozygosity for the specific allele. When 
both probes fluoresce at the same time, it indicates heterozygosity for both alleles (fig. 2.1). 
Quantitative results are available directly after PCR with no additional purification or 
analysis steps (Shen et al. 2009). The Taqman® method has been shown to be very 
successful in the detection of SNPs. It has been used to characterize the APOE haplotypes in 
Alzheimer’s disease (Livak 1999) and has been used to identify an association between the 
5’UTR region and autism (Skaar et al. 2005). 
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Fig. 2.1: Schematic diagram of the Taqman® SNP Genotyping Assay technique 
(http://www.servicexs.nl/dbres/?t=158) 
 
 
2.6 SNP SELECTION AND PRIMER DESIGN 
The exonic SNP (rs3622691) and intronic SNP (rs736707) on the RELN gene was identified 
from a previous experiment carried out by Serajee et al. (2006). The SNP sequence was 
blasted against the Homo sapiens genome using the BLAST tool at NCBI 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). Primers were then manufactured by Applied 
Biosystems according to the specifications as indicated by the File Builder application. The 
Taqman® Custom Genotyping Assay probes (40x) were labelled VIC and FAM to the 
following sequences respectively:  
Exon 22: 5’- TTCTTTGGGTGATTTCATCCTG -3’ and 5’- CCGTCTCTGT 
TTGTATGTGCG - 3’  
Intron 59:  5’- GCAGGGCTGACAGGTTACAC -3’ and 5’-TGGTCTCCTC 
TATCAAAGTT GGC -3’ 
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2.7 PCR PREPARATION  
All samples were diluted with double distilled water (ddH20) to a final concentration of 20 
ng/μl and then aliquoted individually into 96-deepwell plates (Applied Biosystems, USA). 
The first row of each 96 deep-well plate contained he negative control, which consisted of 50 
µl ddh20. A PCR mastermix was prepared by adding 1650 μl of Taqman® Universal 
Genotyping Mastermix (Applied Biosystems, USA) to a microfuge tube. To the tube, 165 μl 
of 20x Taqman® SNP Custom Genotyping Assay (Applied Biosystems, USA) was added, 
along with 825 μl of SABAX water. The solution was then vortexed for 10 sec. The 
Microfuge epMotion 5070 automated pipetting system (Applied Biosystems, USA) was then 
used to transfer the samples and mastermix into the 384-well plate (Applied Biosystems, 
USA) yielding a final volume of 5 µl. 
 
2.8 PCR AMPLIFICATION AND TAQMAN® READING  
The Perkin Elmer 9700 PCR System (Applied Biosystems, USA) was used for PCR 
amplification. PCR parameters were as follows: 
 
• Initial denaturation for 10 min at 95°C  
• Denaturation for 15 sec at 92°C            
• Annealing for 1 min at 60°C                  40 cycles 
• Extension for 1 min at 60°C  
 
Results from the amplified PCR products were viewed using the Applied Biosystems 
7900HT Real-Time PCR System.  
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2.9 MICROARRAY PREPARATION 
10 μl of each sample analysed on the Agilent 2100 Bioanalyzer (Inqaba Biotech, South 
Africa) in order to detect whether the samples had the sufficient concentration of 10 ng/µl 
(Appendix IV). Samples that did not meet the specified requirements were optimized and re-
sent to be analysed. Once all samples met the specified requirements, they were shipped to 
Nimblegen, Iceland where they were subjected to high throughput microarray analysis. 
 
2.10 STATISTICAL ANALYSIS  
2.10.1 Taqman® analysis 
Allele frequencies for the A, G and C variants were calculated using the Hardy-Weinberg 
equation. The Fishers Exact test was performed to compare the number of alleles of the South 
African autistic group to the South African control group at a confidence interval of 95% 
(Esau et al. 2008) and the odds ratio was calculated using the standard 3-by-2 table method 
(http://ihg2.helmholtz-muenchen.de ihg/snps.html) 
 
2.10.2 Microarray analysis 
The microarray data were analysed using the ArrayStar3TM software for gene expression 
analysis (DNASTAR inc, USA). The F-ANOVA test was used to compare gene expression 
values for each gene in the samples. The test was set to detect which genes were more than 
95% significant in all samples.  
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3.1 SNP DATA FOR AUTISTIC AND CONTROL SAMPLES 
 
 
Genotyping results for SNPs in exon 22 (rs3622691) and intron 59 (rs736707) were obtained 
following PCR amplification and viewing with the Applied Biosystems 7900HT Real-Time 
PCR System. The data was displayed in graphical output files (figs. 3.1 and 3.6) for the 
autistic and control population, as well as the non-template controls.  
 
3.1.1 Taqman® genotyping data for rs3622691 
In the autistic group, 148 samples (62 Black, 43 Caucasian and 43 Coloured) were 
genotyped. In the control group, 203 samples (92 Black, 49 Caucasian and 62 Coloured) were 
genotyped. For the Taqman® SNP Assay, blue dots indicate homozygosity for allele G, red 
dots indicate homozygosity for allele C and green dots indicate heterozygosity for alleles CG 
(fig. 3.1). No amplification was observed in the non-template controls, thus ruling out the 
possibility of contamination. The frequencies of the case-control genotypes for the different 
population groups investigated in this study are provided in figs. 3.2, 3.3 and table 3.1. 
Genotype data was used to determine the G- and C- allele frequencies in the different study 
populations (table 3.1; figs. 3.4 and 3.5) 
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Fig. 3.1: Representation of Taqman® SNP Genotyping Assay data analysis for rs 3622691. Allele X=C 
and Allele Y=G. The red dots indicate homozygosity for allele C in both SNPs and the green dots 
indicates heterozygosity for alleles CG (rs3622691). The black cluster represents the non-template 
controls. 
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Fig. 3.2: Percentage of genotype distributions for rs3622691 on RELN in an autistic South African 
population. 
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Fig. 3.3: Percentage of genotype distributions for rs3622691 on the RELN gene in a healthy South African 
population. 
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Table 3.1: Allelic distributions of rs3622691 on RELN in 3 distinct ethnic groups in the South African 
autistic and healthy population. 
 
Ethnic 
Group 
Number Genotype (%) P-value Allele (%) P-value 
  G/G G/C C/C  C Allele G Allele  
Total  South African     
Autistic 148 124 (84) 19 (13) 5 (3) 0.11326 29 (10) 267 (90) 0.89535 
Control 203 164 (81) 37 (18) 2 (1)  41 (10) 365 (90)  
 
OR (95% CI) 
 
1 
 
0.20 
(0.04-1.16) 
 
 
0.30 
(0.06-1.59) 
    
SA Black     
Autistic 60 54 (90) 5 (8) 1 (2) 0.31662 7 (10) 64 (90) 0.50647 
Control 96 81 (84) 15 (16) 0 (0)  15 (8) 177 (92)  
 
OR (95% CI) 
 
1 
 
0.50 
(0.17-1.46) 
 
 
4.49 
(0.18-112.17) 
 
    
SA Caucasian  
Autistic 45 38 (84) 5 (11) 2 (4)  9 (10) 81 (90)  
Control 48 39 (81) 9 (19) 0 (0)  9 (9) 87 (91)  
 
OR (95% CI) 
 
1 
 
0.57 
0.18-1.86 
 
 
5.13 
(0.24-110.36) 
 
 
0.68334 
   
0.88544 
SA Coloured     
Autistic 43 32 (74) 9 (21) 2 (5) 13 (15) 73 (85) 
Control 59 45 (76) 12 (20) 2 (3) 16 (14) 102 (86) 
 
OR (95% CI) 
 
1 
 
1.06 
(0.40-2.80) 
 
 
1.406 
(0.19-10.51) 
 
 
0.82993 
   
0.75317 
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Fig. 3.4: Percentage of the C and G allelic distributions for rs3622691 on RELN in an autistic South 
African population. 
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Fig. 3.5: Percentage of the C and G allelic distributions for rs3622691 on RELN in a healthy South 
African population. 
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3.1.2 Taqman® genotyping data for rs736707 
In the autistic group, 140 samples (59 African, 39 Caucasian and 42 Coloured) were 
genotyped. In the control group, 216 samples (98 Black, 56 Caucasian and 62 Coloured) were 
genotyped. For the Taqman® SNP Assay, blue dots indicate homozygosity for allele G, red 
dots indicate homozygosity for allele A and green dots indicate heterozygosity for alleles AG 
(fig 3.6). No amplification was observed in the non-template controls, thus ruling out the 
possibility of contamination. The frequencies of the case-control genotypes for the different 
population groups investigated in this study are provided in figs. 3.7, 3.8 and table 3.2. 
Genotype data was used to determine the G- and C- allele frequencies in the different study 
populations (table 3.2; figs. 3.9 and 3.10). 
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Fig. 3.6: Representation of Taqman® SNP Genotyping Assay data analysis for rs736707. Allele X=A and 
Allele Y=G. The red dots indicate homozygosity for allele A in both SNPs and the green dots indicates 
heterozygosity for alleles AG (rs736707). The black cluster represents the non-template controls. 
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Fig 3.7: Percentage of genotype distributions for rs736707 on RELN in an autistic South African 
population. 
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Fig 3.8: Percentage of genotype distributions for rs736707 on RELN in a healthy South African 
population. 
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Table 3.2: Allelic distributions of rs736707 on RELN in 3 distinct ethnic groups in the South African 
autistic and healthy population.  
 
Ethnic Group Number Genotype (%) P-value Allele (%) P-value 
  A/A A/G G/G  A Allele G Allele  
Total South African     
Autistic 140 73 (52) 56 (40) 11 (8) 0.00372 202 (72) 78 (28) 0.0009 
Control 216 79 (36) 101 (47) 36 (17)  259 (60) 173 (40)  
 
OR (95% CI) 
    
     1 
       
      0.60 
(0.38-0.95) 
       
      0.33 
(0.16-0.70) 
       
    0.578 
(0.42-0.80) 
 
SA African     
Autistic 56 22 (39) 23 (41) 11 (20) 0.09208 67 (60) 45 (40) 0.08004 
Control 99 26 (26)  46(46) 27 (27)  98 (49) 100 (51)  
 
OR (95% CI) 
      
     1 
 
0.60 
(0.28-1.26) 
 
0.49 
(0.20-1.19) 
    
SA Caucasian     
Autistic 44 22 (50) 22 (50) 0 (0) 0.37300 66 (75) 22 (25) 0.76913 
Control 56 33 (59) 20 (36) 3 (5)  86 (77) 26 (23)  
 
OR (95% CI) 
 
 
1 
 
1.650 
(0.73-3.71) 
 
0.213 
(0.01-4.32) 
 
    
 
SA Coloured     
Autistic 40 29 (72) 11 (28) 0 (0) 0.00009 69 (86) 11 (14) 0.00014 
Control 61 20 (33) 35 (57) 6 (10)  75 (61) 47 (39)  
 
OR (95% CI) 
 
1 
     0.217 
(0.09-0.53) 
     0.053 
(0.003-1.0) 
 
 
 
     0.254 
(0.12-0.53) 
 
 
Values in red indicate significant P-values. P < 0.001 indicates high significance. 
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Fig 3.9: Percentage of the A and G allelic distributions for rs736707 on the RELN gene in an autistic 
South African population. 
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Fig 
3.10: Percentage of the A and G allelic distributions for rs736707 on the RELN gene in a healthy South 
African population. 
 
 
 
 
 
 
 
 
 
 
 
 
 
46 
 
3.1.3 Genotyping analysis  
 
 
3.1.3.1 rs3622691 
 
In the total (autistic and control) South African (SA) population, more than 70% were 
homozygous for the GG genotype. The CC genotype was very low in all ethnic groups, with 
3% in the total autistic sample group and 1% in the total control group (table 3.1). The 
heterozygous genotype CG was low, with 13% and 18% for the autistic and control groups 
respectively (fig. 3.3 and fig. 3.4) 
 
 
The SA total autistic population displayed the GG genotype at 84%, the CG genotype at 13% 
and the CC genotype at 3% (table 3.1). In the SA Black autistic group, 90% of individuals 
were homozygous for the GG genotype and 84% of the control sample was homozygous for 
the GG genotype. The heterozygous genotype CG was 8% for the autistic group and 16% for 
the control. Genotype CC was least prominent, displaying 2% for the autistic sample and 0% 
for the control sample. For allele frequency analysis in the SA Black autistic and control 
sample group, the minor C allele was observed in 10% and 8% of individuals, respectively 
(table 3.1). 
 
For the SA Caucasian autistic group, 84% of individuals were homozygous for the GG 
genotype and 81% for the control group (table 3.1). The heterozygous CG genotype was 11% 
in the autistic group and 19% in the control group. The homozygous CC genotype displayed 
the lowest value for both samples, with 4% in the autistic sample and 0% in the control 
sample. Overall, the C allele was prevalent in the 10% of the autistic Caucasian group and 
9% in the control group (table 3.1). 
 
 
 
 
 
47 
 
The SA Coloured population displayed the homozygous GG genotype in 74% of individuals 
in the autistic sample and 76% in the control sample (table 3.1). The heterozygous genotype 
CG was 21 for the autistic group and 20% for the control. The homozygous CC genotype was 
very low, indicating 5% for the autistic sample and 3% for the control sample. In contrast to 
the other groups screened in the present study, the SA mixed group displayed the highest 
numbers for the C allele, occurring with a frequency of 15% in the autistic group and 14% in 
the control group (table 3.1).  
 
The Fishers exact test indicated no significant difference between the genotype and allele 
frequencies for the autistic and control groups, with all P-values being above 0.05. 
 
 
3.1.3.2 rs736707 
 
The SA total autistic population displayed the AA genotype at 52%, the AG genotype at 40% 
and the CC genotype at 8% (table 3.2). In the SA Black, 39% of the autistic group and 26% 
of the control sample were homozygous for the AA genotype. The heterozygous genotype 
AG frequency was 41% for the autistic group and 46% for the controls. The GG was 
observed in 20% of the SA Black autistic population, and in 27% of the control group (table 
3.2). In the SA Black autistic group, 60% had the A allele as opposed to 40% who had the G 
allele. In the Black control group, 49% displayed the A allele and 51% displayed the G allele 
(table 3.2). 
 
For the SA Caucasian autistic group, 50% of individuals were homozygous for the AA 
genotype, 50% were heterozygous for the AG genotype and 0% was homozygous for the GG 
genotype. For the control group 59% of individuals were homozygous for the AA genotype, 
36% was heterozygous for the AG genotype and only 5% was homozygous for the GG 
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genotype (table 3.2). In the SA Caucasian autistic group, the A allele was observed in 75% of 
individuals and 25% carried the G allele. In the control group, 77% had the A allele and 23% 
the G allele (table 3.2) 
 
The SA Coloured population displayed the homozygous AA genotype in 72% of individuals 
in the autistic sample and only 33% in the control samples. The heterozygous genotype AG 
was 28% for the autistic group and 57% for the control group. The homozygous GG genotype 
was low, observed in only 10% for the control sample and 0% for the autistic sample (table 
3.2). The A allele was most prevalent in the SA Coloured autistic group, occurring at a 
frequency of 86%, whereas only 14% displayed the G allele. In the SA Coloured control 
group, 61% carried the A allele and 39% the G allele (table 3.2). 
 
 
The odds ratio of 0.58 in the SA total group (table 3.2) indicates that individuals possessing 
the G allele are 42% less likely to develop autism. More so, the test also indicates that 
individuals who possess the G allele and form part of the SA Coloured population is 75% less 
likely to develop autism. This indicates that in the Coloured population the G allele acts as 
the protective allele while the A allele indicates predisposition to autism. 
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3.2 GENE EXPRESSION DATA 
 
3.2.1 Expression analysis 
 
All data was obtained using ArrayStar 3 software (DNASTAR inc, USA). The F-ANOVA 
test was set to output genes that were more than 95% significant. Twenty-one genes were 
found in all samples, most of which reside on chromosome 8. The output data indicated start 
and stop codons for each gene as well as the chromosome number and URL for retrieval of 
gene information. The list of genes names are in the ‘notes’ column of the table.  
 
Table 3.3: Candidate genes identified from microarray data (ArrayStar 3 software, DNASTAR inc,           
                  USA) 
 
 
 
Several genes found belong to the primate-specific FAM90A gene family, which originated 
from multiple duplications and rearrangements (Bosch et al. 2007). The transcribed portions 
of all FAM90A genes share at least 93% nucleotide identity. Bosch et al. 2007 divided the 
FAM90A genes into subfamilies I and II based on differences in their upstream and 5-prime 
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UTR sequences. All the FAM90A genes found belong to subfamily II and are characterized 
by a 1.2-kb segment lacking repetitive elements at their 5-prime ends. 
 
Most genes displayed were hypothetical proteins (all genes with prefix LOC). These 
hypothetical proteins existences have been predicted, but there is no experimental evidence 
that it is expressed in vivo. The usual scenario involving a hypothetical protein is in gene 
identification i.e. when the bioinformatic tool used for the gene identification finds a large 
open reading frame without an analog in the protein database, it returns "hypothetical 
protein" as an annotation remark. The BTNL8 (butyrophilin-like 8) gene was also found, of 
which its function is still unknown (http://www.ncbi.nlm.nih.gov/). 
 
The DEFB4 (defensin, beta 4) gene forms part of a family of microbicidal and cytotoxic 
peptides made by neutrophils. Members of the defensin family are highly similar in protein 
sequence. This specific gene encodes defensin, beta 4, an antibiotic peptide which is locally 
regulated by inflammation (http://www.genecards.org/cgi-bin/carddisp.pl?gene=DEFB4).    
 
The HNRNPA1 gene belongs to the A/B subfamily of ubiquitously expressed heterogeneous 
nuclear ribonucleoproteins (hnRNPs). The hnRNPs are RNA binding proteins and they 
complex with heterogeneous nuclear RNA (hnRNA). These proteins are associated with pre-
mRNAs in the nucleus and appear to influence pre-mRNA processing and other aspects of 
mRNA metabolism and transport (http://www.genecards.org/cgi-
bin/carddisp.pl?gene=HNRNPA1). 
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3.2.2 Line graphs  
Following the F-ANOVA testing, the twenty-one genes found were stipulated on line graphs 
using the ArrayStar3 software (DNASTAR inc, USA).  Output data of twenty-one line graphs 
were achieved. These line graphs plots the expression levels for the selected genes over each 
experiment (sample), and then connects the data points with a line so that expression levels 
are shown relative to one another. Expression levels are plotted vertically along the Y-axis 
[log (base 2) scale], while the X-axis represents the sample. Each line represents a specific 
gene; the higher the position of the line graph, the greater the gene expression and conversely 
the lower the position, the less gene expression.  
 
 
Fig. 3.11: Line graphs indicating all twenty-one gene expression levels in each sample (ArrayStar 3 
software, DNASTAR inc, USA). 
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Fig. 3.12: Expression level of the BTNL8 gene in all samples (ArrayStar 3 software, DNASTAR inc, USA) 
  
 
The line graph depicts the BTNL8 gene expression level in all nine samples. It depicts autistic 
5 having the highest level of expression for this gene. However, since this line graph is 
stipulated below an expression level of 12, the gene itself is not as expressed as the other 
genes found in the samples. Thus, the expression levels for all samples can be deemed as very 
low when compared to other genes. 
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Fig. 3.13: The line graphs represent expression levels for FAM90A14, FAM90A7 and FAM90A4P in all 
samples.  
From top to bottom: FAM90A14, FAM90A7, FAM90A4P (ArrayStar 3 software, DNASTAR inc, USA). 
 
The three line graphs depicts the epression levels of three genes in all nine samples. All three 
genes seems to be highly expressed in the samples with FAM90A14 showing the highest level 
of expression. Once again, autistic 5 sample has the highest expression level for these genes, 
whereas autistic 1 and control 3 depicts the lowest level of expression for these genes.  
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Fig. 3.14: The line graphs represent the expression levels of LOC645681, LOC645685, FAM90A10, 
FAM90A13. FAM90A3, FAM90A18 and FAM90A5 in all samples.  
From top to bottom: LOC645681, LOC645685, FAM90A10, FAM90A13. FAM90A3, FAM90A18, 
FAM90A5 (ArrayStar 3 software, DNASTAR inc, USA) 
. 
These line graphs depict the expression levels of 7 genes, including five from the FAM90A 
family and two hypothetical proteins. The two hypothetical proteins indicate the highest level 
of expression, with autistic sample 4 and 5 showing the most expression taking place. 
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Fig. 3.15: The line graphs respresent the expression levels of LOC 349196 and LOC 643368  in all 
samples.    From top to bottom:  LOC 349196, LOC 643368 (ArrayStar 3 software, DNASTAR inc, USA) 
 
These graphs represent two hypothetical proteins. In LOC349196, autistic 4 and 5 show the 
highest expression level for this gene while control 1 and 3 shows the lowest. However, in 
LOC543368, control 2 depicts the highest level of expression, whereas autistic samples 2 and 
3 depict the lowest. 
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Fig. 3.16: The line graphs represent the expression levels for LOC 645362, LOC645489 and DEFB4 genes 
in all samples.  
From top to bottom: LOC 645362, LOC645489, DEFB4 (ArrayStar 3 software, DNASTAR inc, USA). 
 
These three line graphs indicate two hypothetical proteins and the DEFB4 gene, with the 
hypothetical proteins showing the most expression. These genes is shown to be highly 
expressed in samples autistic 4 and 5 as oppose to the control samples.  
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Fig. 3.17: The line graphs represent expression levels for LOC83459 and KIAA0738 in all samples. 
From top to bottom: LOC83459, KIAA0738 (ArrayStar 3 software, DNASTAR inc, USA) 
 
The two line graphs in fig. 3.17 represent two hypothetical proteins, of which LOC83459 is 
highly expressed. LOC83459 is highly expressed in autistic 5 and control 3 and KIAA0738 is 
highly expressed in autistic 2 and autistic 5.  
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Fig. 3.18: The line graph repesents the epression level of the HNRNPA1 gene in all samples (ArrayStar 3 
software, DNASTAR inc, USA) 
 
This graph indicates the expression level for the HNRPA1 gene where the gene is highly 
expressed in autistic 1, autistic 5 and control 3. Little expression occurs in autistic 6 and 
control 2.  
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Fig. 3.19: The line graphs represent the expression levels of LOC643788 and LOC441426 in all samples. 
From top to bottom: LOC643788,  LOC441426 (ArrayStar 3 software, DNASTAR inc, USA) 
 
These line graphs are indicative of genes that were very highly expressed in the samples. 
Autistic samples 2 and 5 shows the highest level of expression for these genes whereas 
autistic 4 and control 2 show the least. 
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3.2.3 Heat map 
The heat map is another graphical form of analysing data using the ArrayStar3 software 
programme (DNASTAR inc, USA). The graphical output uses colour variants to indicate the 
level of expression of each gene within a sample. The columns represent the sample number 
and the rows represent the accession number of each gene. Each colour depicts the degree of 
expression. Blue indicates highly suppressed genes, yellow indicates mildly expressed genes, 
red indicates highly expressed genes and the light grey indicates missing values. 
 
 
Fig. 3.20: The heat map uses colour to represent and compare expression levels of 21 genes in all samples 
(ArrayStar 3 software, DNASTAR inc, USA) 
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Table 3.4: The 21 genes that were expressed in the samples are listed below.  
 
                 
Number 
Accession Number Gene Name Function 
  1 AY358523 BTNL8 Function unknown 
2 XM_496945 FAM90A4          
             The functions of these genes are not    
              specified. These genes belong to the  
              sub-family II of the primate-specific  
              FAM90A gene family, which  
              originated from multiple    
              duplications and rearrangements 
 
3 XM_372013 FAM90A3 
4 XM_496946 FAM90A13 
5 XM_496955 FAM90A18 
6 XM_496948 FAM90A7 
7 XM_496957 FAM90A10 
8 XM_928665 FAM90A14 
9 XM_496947 FAM90A5 
10 XM_926698 LOC643368 Hypothetical protein 
11 NM_004942 DEFB4 This gene forms part of a family of 
microbicidal and cytotoxic peptides made by 
neutrophils. This specific gene encodes 
defensin, beta 4, an antibiotic peptide which 
is locally regulated by inflammation 
12 NM_014719 KIAAO738 Hypothetical protein 
13 XM_928684 LOC645683 Hypothetical protein 
14 XM_928690 LOC645681 Hypothetical protein 
15 XM_928404 LOC645362 Hypothetical protein 
16 XM_928514 LOC645489 Hypothetical protein 
17 NM_001025473 LOC349196 Hypothetical protein 
18 BC 090061 LOC83459 Hypothetical protein 
19 NM_001013727 LOC441426 Hypothetical protein 
20 NM_927069 LOC643788 Hypothetical protein 
21 BC 103707 HNRPA1 This gene is associated with pre-mRNAs 
in the nucleus and appear to influence 
pre-mRNA processing and other aspects 
of mRNA metabolism and transport 
Text highlighted in blue indicate highly suppressed genes. Text highlighted in yellow indicate mildly 
expressed genes. Text in bold and highlighted in red indicate genes that were highly expressed. 
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The heat map indicates that the BTNL8 gene is suppressed (not highly expressed) in autistic 
1, autistic 3, autistic 6, control 1 and control 3. This finding supports the data shown in the 
line graph (fig 3.12). 
 
Genes 2-12 (table 3.4) are mildy expressed in all the samples and genes 13-21 (table 3.4) are 
highly expressed in autistic samples when compared to controls. Hypothetical protein 
LOC83459 and LOC643788 is expressed the most in autistic 5 (fig 3.20). 
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4.1 DISCUSSION 
This SNP study was aimed at identifying the genotyping frequencies and allelic distributions 
of SNPs rs3622691 and rs736707 of the RELN gene in three major autistic and healthy ethnic 
groups in the SA population.  The microarray study was aimed at identifying candidate genes 
using cDNA microarray, which are either up or down-regulated in the SA autistic population. 
 
4.1.1 SNP analysis 
When preparing DNA samples for the Taqman® SNP Genotyping assay, the dilution step 
was the most important as it was done manually and highly prone to error. Therefore, all 
dilutions were done carefully and under sterile conditions, in order to avoid contamination. 
The Taqman® protocol as well as the Eppendorf epMotion automated pipetting system had 
proven to be a very effective and time efficient. This system reduces the risk of human error 
and contamination. Non-template samples were used in order to detect the presence of any 
possible that might have occurred. In this experiment, the non-template controls indicated no 
contamination amongst the samples. 
 
4.1.1.1 SNP in exon 22 (rs3622691) 
 
The GG genotype was shown to be the most prominent amongst all ethnic groups in the 
autistic and healthy samples. The CC genotype occurred at the lowest frequency, indicating 
values between 0% and 5% in all autistic and healthy ethnic groups. The GG genotype 
showed to be higher in the SA Black and SA Caucasian autistic groups when compared to 
their controls. The same was seen for the CG allele in the Black and Caucasian sample group. 
However, the GG and CG genotypes seemed to be slightly lower in the SA Coloured group, 
as oppose to their control group (table 3.1).  
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The SA total population displayed same results for the distribution of A and G alleles in both 
the autistic and control groups, with the G allele being distributed amongst 90% of 
individuals and the C allele only 10%. Allele distribution for G was shown to be similar in all 
autistic and control ethnic groups, with differences of about 1% or 2%. Similarity occurs with 
the C allele as well, in all ethnic groups of autistic and control samples (table 3.1). For all of 
the samples that were genotyped, the Fishers exact test showed no significance of the SNP, 
rs3622691 in both the SA healthy and autistic population. 
 
4.1.1.2 SNP in intron 59 (rs736707) 
 
In the SA total autistic population, the AA genotype showed a higher frequency, present in 
more than 50% of sample group. The AG genotype was present in 40% of the groups with 
only 8% possessing the GG genotype. However, the total control population was predominant 
for the AG allele at 47%, with only 37% possessing the AA allele. The SA Black autistic and 
control group had similar values, with the AG genotype being predominant in both groups 
and the GG genotype being the least dominant (table 3.2). The AA and AG genotypes were 
equally shared amongst the SA Caucasian autistic group, indicating that 50% of individuals 
possessed the AA and AG genotypes respectively. The control showed to be more dominant 
for the AA group (table 3.2). It was evident that most of the Coloured population possessed 
the AA genotype (72%), with 0% of them possessing the GG genotype. Only 33% of the 
mixed control group possessed the AA genotype with most of them possessing the AG 
genotype (57%).  
 
The A allele was dominant in all ethnic groups, with 72% of the total autistic population and 
60 % of the total control group. When analyzing each ethnic group, it was evident that the A 
allele was predominant in the Coloured autistic group, with 86% possessing the A allele and 
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only 14% of the Coloured control group possessing the G allele (table 3.2). The Fishers exact 
test indicated a significant p-value of 0.0009, with an odds ratio of 0.58 in the total 
population group (table 3.2). This indicates that individuals possessing the G allele in the 
total sample group are 42% less likely to develop autism. The significantly higher frequency 
of the G allele in the controls suggests that this allele might be protective against developing 
autism. Taken together, these data indicate that those individuals in this sample group who 
possess the A allele would be more susceptible to autism than those who have the G alelle. 
This poses true for the Coloured autistic group, where 72% had the AA genotype and none 
had the GG genotype. The p-value was also highly significant for the Coloured group, where 
the odds ratio was 0.25. Hence, the individuals in the mixed autistic sample group were 75% 
less likely to develop autism had they had the G allele rather that the A allele.  
 
These results are highly significant and indicate that the SNP rs736707 in intron 59 of the 
RELN gene is associated with autism in the Coloured autistic sample group. However, 
Serajee et al. 2006 found this SNP to be implicated in a Caucasian autistic population. South 
Africa’s cultural heritage is much diversified, with Coloured groups having ancestors from 
various parts of the world. This could explain the allele differentiation of the Coloured group 
as opposed to the Caucasian and Black sample group.  
 
4.1.2 Expression analysis 
Since the microarray service was in Iceland (Nimblegen, Iceland), it was suggested that RNA 
or cDNA blood samples be shipped, as it would be more stable. Since blood is invasive, only 
a total of six autistic and three healthy samples could be used for this experiment. The first 
experimental attempt made was shipping cDNA blood samples, but the cDNA amount sent 
was not sufficient for analysis. The experiment had to be redone with changes to the protocol. 
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RNA samples were shipped on dry ice the second time after being analysed using the 
Bionanalyser (Inqaba Biotech, South Africa) to check the quality and quantity of RNA for 
microarray analysis.  
 
Results, contained on a disk, was shipped back with documents which required the 
ArrayStar3 software (DNASTAR inc, USA) to work. The software uses the F-ANOVA for 
statistical analysis of more than three samples. Since nine samples were used in this study, 
the F-ANOVA test deemed sufficient. The test indicated a total of twenty-one genes (table 
3.3) that had more than 95% significance in these samples. The data was stipulated on line 
graphs and a heat map.  
 
4.1.2.1 Autistic candidate genes 
 
The genes found were mostly hypothetical genes as well as genes belonging to the FAM90A 
family. The various line graphs indicated the expression levels of all genes in the nine 
samples, with the LOC83459 (fig 3.17) gene showing the highest level of expression and the 
BTNL8 (fig 3.12) gene showing the least. Sample number autistic 5 showed to have the 
highest expression level for most of the genes, with the LOC83459 gene being highly 
expressed in this sample, as opposed to controls (fig 3.21). The heat map also indicated that 
the BTNL8 gene, for which there is no specified function, is suppressed in all samples 
(especially the control samples). The DEFB4 gene and HNRPA1 gene showed to be mildly 
expressed in all samples. All genes belonging to FAM90A family showed to be mildly 
expressed in most samples with higher expression taking place in autistic 4 and autistic 5.  
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4.2 CONCLUSION 
In conclusion, I have shown that there was no significant association of rs3622691 of the 
RELN gene in the autistic SA population compared to the healthy SA population. However, 
there was a strong association of rs736707 of the RELN gene in the Coloured South African 
autistic population, indicating a highly significant p-value of 0.00014. It was also shown that 
the G allele serves as a protective allele in this specific population, whilst the A allele 
indicates predisposition to autism.  
 
I have also identified 21 candidate genes, which are differentially expressed, using high 
throughput cDNA microarray technology. The LOC83459 showed the highest level of 
expression in the autistic samples (especially autistic 5), while the BTNL8 gene was shown to 
be highly suppressed in the control samples. Thus, I have met my aims and shown, on a small 
scale, that specific genes does indeed play a role in autism.  
 
4.2.1 Future studies 
Future studies could include the analysis of SNPs in candidate genes (FOXP2, NLGN4X, 
EN2) said to be involved in other autistic populations, as well as looking at their ancestral 
heritage and whether it plays a role in the aetiology of autism.  
 
Also, candidate genes found using the microarray technique could be further analysed using 
RT-PCR. The shortcomings of the microarray study were that it was very costly, only a small 
sample group was used and the sample collection was invasive. Since samples collection 
were from a specific ethnic and age group, I suggest that future studies should include a 
larger sample group and different ethnicities; for example, repeating this microarray study  
using a larger sample size in a SA Coloured group and in a SA Black group. 
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Since several genes are said to be involved in autism (Bailey et al. 1995), the genes found in 
this study are merely a stepping stone in the right direction. More genetic studies still need to 
be done. Currently, an enormous amount of focus has been placed on genetics of autism and I 
foresee answers that will lead to the aetiology, understanding and treatment of this disorder. 
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GLOSSARY 
 
 
Allele frequency – Allele frequency is the number of copies of a particular allele divided by 
the number of copies of all alleles at the genetic place (locus) in a population. It can be 
expressed for example as a percentage. In population genetics, allele frequencies are used to 
depict the amount of genetic diversity at the individual, population, and species level. 
Alzheimer’s disease – This is the most common form of dementia. It is an incurable, 
degenerative, and terminal disease that is unique for every individual. The earliest 
observable symptoms are often mistakenly thought to be 'age-related' concerns, or 
manifestations of stress.[6] In the early stages, the most commonly recognised symptom is 
memory loss, such as difficulty in remembering recently learned facts.  
Blood-brain barrier – This is a membrane that controls the passage of substances from the 
blood into the central nervous system. It is a physical barrier between the local blood vessels 
and most parts of the central nervous system itself, and stops many substances from 
travelling across it. 
 
Candidate genes - A candidate gene is a gene located in a chromosome region suspected of 
being involved in the expression of a trait such as a disease, whose protein product suggests 
that it could be the gene in question. 
 
CAT scan – Computed Axial Tomography (CAT) scan is a medical imaging method 
employing tomography where digital geometry processing is used to generate a three-
dimensional image of the internals of an object from a large series of two-dimensional X-ray 
images taken around a single axis of rotation. 
 
Cognition – This term is used in several loosely related ways to refer to a faculty for the 
human-like processing of information, applying knowledge and changing preferences. 
 
Confidence interval - In statistics, a confidence interval (CI) is a particular kind of interval 
estimate of a population parameter. Instead of estimating the parameter by a single value, an 
interval likely to include the parameter is given. Thus, confidence intervals are used to 
indicate the reliability of an estimate. 
 
Cytogenic studies - Cytogenetics is the study of the structure of chromosome material. It 
includes routine analysis of G-Banded chromosomes, other cytogenetic banding techniques, 
as well as molecular cytogenetics such as fluorescent in situ hybridization (FISH) and 
comparative genomic hybridization (CGH). 
Exon - An exon is a nucleic acid sequence that is represented in the mature form of an RNA 
molecule after either portions of a precursor RNA (introns) have been removed by cis-
splicing or by two or more precursor RNA molecules have been ligated by trans-splicing. 
 
F-ANOVA test - A F-test is any statistical test in which the test statistic has an F-
distribution under the null hypothesis. The best know F-test is ANOVA, with the hypothesis 
that the means of several normally distributed populations, all having the same standard 
deviation, are equal.  
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Fetal alcohol syndrome (FAS) - FAS is a pattern of birth defects, learning, and behavioral 
problems affecting individuals whose mothers consumed alcohol during pregnancy. 
 
Fishers exact test - This is a statistical significance test used in the analysis of contingency 
tables where sample sizes are small. It is named after its inventor, R. A. Fisher, and is one of 
a class of exact tests, so called because the significance of the deviation from a null 
hypothesis can be calculated exactly, rather than relying on an approximation that becomes 
exact in the limit as the sample size grows to infinity, as with many statistical tests. 
Fragile X Syndrome – This is a genetic syndrome which results in a spectrum of 
characteristic physical, intellectual, emotional and behavioural features which range from 
severe to mild in manifestation.The syndrome is associated with the expansion of a single 
trinucleotide gene sequence (CGG) on the X chromosome, and results in a failure to express 
the FMR1 protein which is required for normal neural development. 
Genotype - The genotype is the genetic constitution of a cell, an organism, or an individual 
(i.e. the specific allele makeup of the individual) usually with reference to a specific 
character under consideration 
Haplotype - In genetics, a haplotype is a combination of alleles at multiple loci that are 
transmitted together on the same chromosome. Haplotype may refer to as few as one locus or 
to an entire chromosome depending on the number of recombination events that have 
occurred between a given set of loci. In a second meaning, haplotype is a set of single 
nucleotide polymorphisms (SNPs) on a single chromatid that are statistically associated.  
Hardy-Weinberg equation - The Hardy–Weinberg principle states that both allele and 
genotype frequencies in a population remain constant—that is, they are in equilibrium—from 
generation to generation unless specific disturbing influences are introduced. Those 
disturbing influences include non-random mating, mutations, selection, limited population 
size, "overlapping generations", random genetic drift and gene flow. 
 
Heterozygous - Having different alleles at one or more corresponding chromosomal loci. 
 
Homozygous - Having the same alleles at a particular gene locus on homologous 
chromosomes. 
 
Huntington’s Disease - Huntington's disease, chorea, or disorder, is an incurable 
neurodegenerative genetic disorder that affects muscle coordination and some cognitive 
functions, typically becoming noticeable in middle age. It is the most common genetic cause 
of abnormal involuntary writhing movements called chorea. 
 
Intron - An intron is a DNA region within a gene that is not translated into protein. 
 
MRI scan - Magnetic resonance imaging (MRI) uses a strong magnetic field and radio 
waves to produce detailed pictures of the inside of your body. MRI scans can show muscles, 
joints, bone marrow, blood vessels, nerves and other structures within your body.  
 
Neurodevelopmental disorders – Severe disabling conditions often associated with life-long 
impairment and are recognized to be the result of abnormalities in brain development due to 
both genetic and environmental/biological causes. 
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Phenylketonura - Phenylketonuria (PKU) is an autosomal recessive genetic disorder 
characterized by a deficiency in the hepatic enzyme phenylalanine hydroxylase. 
 
Polymerase Chain Reaction - In molecular biology, the polymerase chain reaction (PCR) is 
a technique to amplify a single or few copies of a piece of DNA across several orders of 
magnitude, generating thousands to millions of copies of a particular DNA sequence. 
 
Restriction Fragment Length Polymorphism - In molecular biology, the term restriction 
fragment length polymorphism, or RFLP, refers to a difference between two or more samples 
of homologous DNA molecules arising from differing locations of restriction sites, and to a 
related laboratory technique by which these segments can be distinguished. 
 
Schizophrenia – This is a psychiatric diagnosis that describes a mental illness characterized 
by impairments in the perception or expression of reality, most commonly manifesting as 
auditory hallucinations, paranoid or bizarre delusions or disorganized speech and thinking 
in the context of significant social or occupational dysfunction.  
 
Sickle Cell Anaemia – This is a genetic life-long blood disorder characterized by red blood 
cells that assume an abnormal, rigid, sickle shape. Sickling decreases the cells' flexibility and 
results in a risk of various complications. 
 
Tourettes Syndrome – This is an inherited neurological disorder with onset in childhood, 
characterized by the presence of multiple physical (motor) tics and at least one vocal 
(phonic) tic; these tics characteristically wax and wane. It is also defined as part of a 
spectrum of tic disorders, which includes transient and chronic tics. 
 
Tuberous Sclerosis Complex -  Tuberous sclerosis complex (TSC) is a rare, multi-system 
genetic disease that causes benign tumours to grow in the brain and on other vital organs 
such as the kidneys, heart, eyes, lungs, and skin. A combination of symptoms may include 
seizures, developmental delay, behavioural problems, skin abnormalities, lung and kidney 
disease. 
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Full names of genes as depicted in table 1.1 
 
GENE ID GENE NAME 
ADA Adenosine deaminase 
APOE2 Apolipoprotein E2 
ARX Aristaless related homeobox 
ATP10C ATPase class V type 10A 
AVPR1A Arginine vasopressin receptor 1A 
C4B Complement component 4B 
EN2 Engrailed homeobox 2 
GABRA5 Gamma-aminobutyric acid (GABA) A 
receptor, alpha 5. 
GABRB3 Gamma-aminobutyric acid (GABA) A 
receptor, beta 3. 
GABRG3 Gamma-aminobutyric acid receptor gamma 3 
subunit 
GLO1 Glyoxalase 1 
GRIK2 Glutamate receptor, ionotropic kainate 2 
Precursor 
HOXA1 Homeobox A1 
HOXB1 Homeobox B1 
HRAS V-Ha-ras Harvey rat sarcoma viral oncogene 
homolog. 
NF1 Neurofibromin 1 
NLGN4X Neuroligin 4, X-linked 
PTEN Phosphatase and tensin homolog 
SLC25A12 Solute carrier family 25 (mitochondrial 
carrier, Aralar), member 12. 
SLC6A4 Solute carrier family 6 (neurotransmitter 
transporter, serotonin), member 4. 
UBE2H Ubiquitin-conjugating enzyme E2H 
UBE3A Ubiquitin protein ligase E3A 
WNT2 Wingless-type MMTV integration site family 
member 2 
 
 
 
 
 
 Appendix I 
 
 
 
    University of the Western Cape 
    _________________________________________________________________ 
 
    Private Bag X17 BELLVILLE 7535 South Africa 
    Telephone:  +27 21 959 2215 Telefax:  +27 21 959 3505 
 
 
 
 
 
 
DEPARTMENT OF BIOTECHNOLOGY 
 
24th August 2007 
 
Alpha School 
Palmerston Road 
Woodstock 
 
Dear Parents/Guardians 
I am lecturing in the Biotechnology department at the University of the Western Cape. I have completed 
my doctoral studies in Human Genetics and I am pursuing a project which examines the genetics of Autism 
in a South African population. This is the first study of its kind done in South Africa. We have recently 
presented and published an article at the 2nd World Congress on Autism in South Africa (2006) and we are 
completing two more articles from results which we have generated in this year. 
 
The success of this study is as a result of the participants and their families. One shortcoming of the project 
was that the sample size of individuals with Autism was too small and therefore, to overcome this obstacle 
we are trying to increase our sample size by collecting as many samples as possible.  
 
These samples are biological material which will be obtained from your child by collecting cheek cells 
from the inside of his/her mouth, using a clean sterile swab. It is a painless and non-intrusive procedure. 
The whole procedure will only take a minute and will be done by properly trained individuals under 
hygienic conditions in their respective classroom in the presence of their teacher.  
 
The project has been approved by the principal, UWC Ethics Committee and the Western Cape Education 
Department. Being the parent/guardian of the child, I seek your permission for the participation of your 
child in this study. 
 
 
Dr Arieff 
 
………………………………. 
 
Dr Zainunisha Arieff 
Dept of Biotechnology 
Email: zarieff@uwc.ac.za 
Tel: (021) 9592214/5 
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Private Bag X17, Belvil le,  7535 
South Africa 
Tel:  +27 (0) 21 959 2215 
Fax: +27 (0)  21 959 3505 
Website:  www.uwc.ac.za 
Department of Biotechnology 
 
September 2008 
 
Dear Parent/Guardian 
 
I am a human genetics Masters student, under the direct supervision of Dr. Z Arieff, at the University of 
the Western Cape. A few of my colleagues and I have been to Vera this year and last year to collect cheek 
cells from your child, which you have consented for. This year, my study involves collecting samples from six 
children and analysing their DNA by looking at which genes are over and under expressed. The results from 
this study will indicate new genes involved in the pathology of Autism. This is a very powerful study and has 
not been undertaken in South Africa, and we anticipate that the results from this study will aid the 
understanding of genetics as a cause of Autism. 
 
In order to do this study, I need blood samples from six boys at Vera school. I’ve been working closely with 
Dr Schlegal. She and Jana Forrester suggested we ask your permission for your child to be involved in our 
study.  Dr Schlegal, together with a nurse, will take the blood sample. 
 
The project has been approved by the principal and the UWC Ethics Committee. If you need any further 
information about this project, please do not hesitate to contact me telephonically or via email. 
 
Yours in anticipation 
 
Hajirah Gameeldien 
 (021) 959 2503 
hajirahg@gmail.com 
 
 
………………………………………………………. 
Dr. Zainuneesha Arieff 
 
 
………………………………………………………. 
Dr. Birgit Schlegal 
FACULTY OF NATURAL SCIENCES  
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Appendix III 
 
Clearly print child’s: Name ………………………………………………………….. 
            Date of birth …………………………………………………… 
        
Please indicate with a cross on the slip, the option which you have chosen.  
 
Option 1:    I hereby give permission for my child to be included in this research. 
 
Option 2:    I hereby give permission for my child to be included in this research 
         and would like more information on the project.    
 
Option 3      I do not give permission for participation in this research.   
 
If you have chosen option 1, please read and fill in the form below: 
 
1. I, ____________________________________________, consent to the use of my/ 
daughter’s/son’s genetic material in the study outlined above. 
  
2.  I understand that the genetic material for analysis is to be obtained from a blood sample. 
 
3. I understand that the sample has been assigned a unique identification number and that there 
will be no link between my child’s name and the unique identification number. 
 
4  Since the sample has been collected anonymously it cannot be withdrawn from the study.   
 
5 The sample will be stored indefinitely. 
  
6 The results of the project will be published in a scientific journal. 
 
7. The analysis procedure only provides information on variable genetic elements on specific 
chromosomes and cannot determine the complete genetic makeup of an individual.  
 
8. At no stage will the sample provided be used for anything other than the analysis of 
biomolecules involved in autism. 
 
9. ALL OF THE ABOVE HAS BEEN EXPLAINED TO ME IN A LANGUAGE THAT I 
UNDERSTAND AND MY QUESTIONS ANSWERED BY: 
 
 Dr Arieff 
 
 
Parent’s/Guardian’s signature: __________________________________ 
 
Dr Zainunisha Arieff 
Dept of Biotechnology 
Email: zarieff@uwc.ac.za 
Tel: (021) 9592214/5 
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1Overall Results for sample 1  :  1
RNA Area: 131.2 
RNA Concentration: 1,061 pg/µl
rRNA Ratio [28s / 18s]: 0.0 
RNA Integrity Number (RIN): 7.6   (B.02.03) 
Result Flagging Color:
Result Flagging Label: RIN: 7.60 
Fragment table for sample 1  :  1
Name Start Size [nt] End Size [nt] Area % of total Area
28S 1,935 4,366 88.0 67.1
2
Overall Results for sample 2  :  2
RNA Area: 323.9 
RNA Concentration: 2,620 pg/µl
rRNA Ratio [28s / 18s]: 0.0 
RNA Integrity Number (RIN): 7.0   (B.02.03) 
Result Flagging Color:
Result Flagging Label: RIN:7 
Fragment table for sample 2  :  2
Name Start Size [nt] End Size [nt] Area % of total Area
28S 1,694 4,623 152.9 47.2
3
Overall Results for sample 3  :  3
RNA Area: 109.4 
RNA Concentration: 885 pg/µl
rRNA Ratio [28s / 18s]: 0.0 
RNA Integrity Number (RIN): 9.0   (B.02.03) 
Result Flagging Color:
Result Flagging Label: RIN:9 
Fragment table for sample 3  :  3
Name Start Size [nt] End Size [nt] Area % of total Area
28S 2,347 4,215 42.3 38.7
4
Overall Results for sample 4  :  4
RNA Area: 384.6 
RNA Concentration: 3,111 pg/µl
rRNA Ratio [28s / 18s]: 0.0 
RNA Integrity Number (RIN): 8.5   (B.02.03) 
Result Flagging Color:
Result Flagging Label: RIN: 8.50 
Fragment table for sample 4  :  4
Name Start Size [nt] End Size [nt] Area % of total Area
28S 2,323 4,395 165.8 43.1
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5Overall Results for sample 5  :  5
RNA Area: 78.1 
RNA Concentration: 632 pg/µl
rRNA Ratio [28s / 18s]: 0.0 
RNA Integrity Number (RIN): 2.6   (B.02.03) 
Result Flagging Color:
Result Flagging Label: RIN: 2.60 
Fragment table for sample 5  :  5
Name Start Size [nt] End Size [nt] Area % of total Area
28S 3,512 3,864 0.5 0.7
6
Overall Results for sample 6  :  6
RNA Area: 33.7 
RNA Concentration: 273 pg/µl
rRNA Ratio [28s / 18s]: 0.0 
RNA Integrity Number (RIN): 2.4   (B.02.03) 
Result Flagging Color:
Result Flagging Label: RIN: 2.40 
Fragment table for sample 6  :  6
Name Start Size [nt] End Size [nt] Area % of total Area
28S 3,698 3,806 0.1 0.4
7
Overall Results for sample 7  :  7
RNA Area: 401.1 
RNA Concentration: 3,244 pg/µl
rRNA Ratio [28s / 18s]: 0.0 
RNA Integrity Number (RIN): 7.0   (B.02.03) 
Result Flagging Color:
Result Flagging Label: RIN:7 
Fragment table for sample 7  :  7
Name Start Size [nt] End Size [nt] Area % of total Area
28S 1,925 4,603 307.9 76.8
8
Overall Results for sample 8  :  8
RNA Area: 601.2 
RNA Concentration: 4,863 pg/µl
rRNA Ratio [28s / 18s]: 339.3 
RNA Integrity Number (RIN): 6.9   (B.02.03) 
Result Flagging Color:
Result Flagging Label: RIN: 6.90 
Fragment table for sample 8  :  8
Name Start Size [nt] End Size [nt] Area % of total Area
18S 1,120 1,328 1.2 0.2
28S 2,160 4,434 423.2 70.4
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9Overall Results for sample 9  :  9
RNA Area: 152.0 
RNA Concentration: 1,230 pg/µl
rRNA Ratio [28s / 18s]: 0.0 
RNA Integrity Number (RIN): 7.9   (B.02.03) 
Result Flagging Color:
Result Flagging Label: RIN: 7.90 
Fragment table for sample 9  :  9
Name Start Size [nt] End Size [nt] Area % of total Area
28S 2,064 4,123 85.5 56.3
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